Home Cellular science Molecular transport applied to signal phase 2 of the first line

Molecular transport applied to signal phase 2 of the first line


SOUTH SAN FRANCISCO, Calif., July 05 10, 2022 (GLOBE NEWSWIRE) — Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT) today announced that the company plans to release the first results of data from its combined Phase 2 MARKET trial of AMT-101. (GI-selective, oral fusion of IL-10) with an anti-TNFα in biologic-naïve patients with moderate to severe ulcerative colitis. The Company will issue a pre-market press release and host a live web conference call on Wednesday, July 6, 2022 at 8:30 a.m. ET (5:30 a.m. PT).

Conference Call and Webcast Information
To join the conference call by phone and participate in the live Q&A session, please pre-register online here to receive a phone number and unique access code required to participate in the call. A live webcast will be available on the Events page of the Applied Molecular Transport website at https://ir.appliedmt.com/news-events/events. An archived replay will be available for 30 days after the event.

About Applied Molecular Transport Inc.
AMT is a clinical-stage biopharmaceutical company developing novel oral biologic product candidates, leveraging its technology platform to engineer biologic product candidates into patient-tailored oral dosage forms. AMT’s product candidates are designed to precisely target relevant disease pathophysiology. AMT’s proprietary technology platform is integrated into its product candidates, leveraging existing natural cellular trafficking pathways to drive the active transport of various therapeutic modalities across the IE barrier. Active transport is an efficient mechanism that uses the cell’s own machinery to transport materials across the IE barrier.

AMT’s corporate headquarters, in-house GMP manufacturing and laboratory facilities are located in South San Francisco, CA. For more information about AMT, please visit www.appliedmt.com.

Contact with Investor Relations:
Andrew Chang
Head, Investor Relations and Corporate Communications
[email protected]

Media contacts:
Alexandra Santos
Wheelhouse Life Science Advisors
[email protected]

Aljanae Reynolds
Wheelhouse Life Science Advisors
[email protected]